Drug Information Related to Peginterferon Alfa-2b
Back
01. MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL. - Free ......
MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has initiated enrollment in a Phase IIb combination therapy combination therapyn. Method of treating disease through the simultaneous use of a variety o...
02. Enzon Announces Schering-Plough In-Licensing Agreement With Roche ......
Business & Health Editors PISCATAWAY, N.J--(BUSINESS WIRE)--Aug. 13, 2001 Enzon, Inc. (NASDAQ:ENZN) announced today that Schering-Plough (NYSE:SGP) has reported that it has entered into a licensing agreement with F.Hoffmann-La Roche Ltd and Hoffmann-La Roche In...
03. FDA ASSIGNS PRIORITY REVIEW STATUS TO PEG-INTRON/REBETOL. - Free Onlin...
Enzon, Inc. (NASDAQ:ENZN), Piscataway, N.J. has announced that
Schering-Plough Corporation (NYSE:SGP) has been notified verbally by the
U.S. Food and Drug Administration (FDA) that priority review status has
been assigned to Schering-Plough's supplemental Biolo...
04. Enzon Announces FDA Assigns Priority Review Status to PEG-INTRON and ....
Business Editors PISCATAWAY, N.J.--(BUSINESS WIRE)--March 23, 2001 Enzon, Inc. (NASDAQ:ENZN) announced today that Schering-Plough Corporation (NYSE:SGP) has been notified verbally by the U.S. Food and Drug Administration (FDA) that priority review status has been a...
05. Enzon Announces Interim Results Of PEG-INTRON Plus REBETOL Studies in ...
Business & Health Editors PISCATAWAY, N.J.--(BUSINESS WIRE)--May 22, 2001 Enzon, Inc. (NASDAQ: ENZN) announced today that Schering-Plough Research Institute has reported interim results of two ongoing investigational clinical studies with once-weekly PEG-INTRON...
06. Schering-Plough launches hepatitis treatment in Europe. - Free Online ...
Schering-Plough Corporation (Kenilworth, NJ) announced that the
PEG-INTRON pre-filled pen (peginterferon alfa-2b) Single-dose Delivery
System for the treatment of hepatitis C is being launched in Europe.
The introduction of the PEG-INTRON pre-filled pen marks a ...
07. FDA APPROVES SCHERING-PLOUGH'S NDA TO MARKET REBETOL. - Free Online Li...
Enzon, Inc. (NASDAQ: ENZN), Piscataway, N.J., has announced that
Schering-Plough Corporation (NYSE:SGP) has reported that it has been
granted marketing approval from the U.S. Food and Drug Administration
(FDA) for REBETOL(R) (ribavirin, USP) Capsules as a separa...
08. Schering-Plough to Initiate First Head-to-Head Study of Leading ......
Schering-Plough Corporation (NYSE: SGP)
today
announced plans to initiate a major clinical study involving 2,880 patients
that for the first time will directly compare the two approved forms of
pegylated interferon therapy(1) for chronic hepatitis C virus (HCV)
infect...
09. PEG-Intron | OB/GYN News | Find Articles at BNET
(peginterferon alfa-2b, Schering-Plough Corp.)
...
10. Schering-Plough Announces FDA Approval of PEG-INTRON REDIPEN(TM) for ....
Schering-Plough Corporation (NYSE: SGP)
today announced that the U.S. Food and Drug Administration (FDA) has
granted marketing approval to PEG-INTRON REDIPEN™, a pre-filled pen for
administering PEG-INTRON® (peginterferon alfa-2b) Powder for Injection,
the m...
11. Schering-Plough Highlights PEGINTRON™ and Boceprevir Hepatitis C Dat...
KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation , a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that data from several clinical studies with PEGINTRON(TM) (peginterferon al...
12. About 60 Clinical Studies Regarding Schering-Plough's Oncology ......
KENILWORTH, N.J., May 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that about 80 posters, poster discussions, and oral presentations from about 60 clinical studies relating to its growing oncology franchise will be presented at the upcomi...
